Intravenous administration of both the 9a,1la-(epoxymethano) and 1la,9a-(epoxymethano) analogues of prostaglandin H2 (0.25 ,ug/kg) produced a prominent rise in pulmonary arterial pressure and a moderate increase in systemic arterial pressure. 2 Direct administration of the endoperoxide analogues (1.25 jg/kg) into the bypass reservoir produced a greater rise in systemic arterial pressure and less prominent rise in pulmonary arterial pressure.
Introduction Methods
The incorporation of molecular oxygen into the polyenoic fatty acid arachidonic acid, yields a cascade of compounds possessing great biological activity. Some of the end products of this metabolic pathway are prostaglandins D2, E, and F2. and the thromboxanes. The initial products of this reaction are prostaglandin endoperoxides (prostaglandins G2 and H2) . The naturally occurring endoperoxides are unstable, possess a short half-life (Hamberg, Svensson, Wakabayashi & Samuelsson, 1974) and produce complex systemic arterial pressure responses when administered intravenously in guinea-pigs (Hamberg, Hedqvist, Strandberg, Svensson & Samuelsson, 1975) .
Recent studies in our laboratory show that three stable synthetic prostaglandin endoperoxide analogues are systemic pressor agents, potent pulmonary vasoconstrictors and exert a direct positive inotropic effect on the heart (Rose, Kot, Ramwell, Doykos & O'Neill, 1976 (Rose, Broida, Hufnagel, Gillespie, Rabile & Freis, 1955) . Prior to initiating bypass, heparin (7 to 8 mg/kg) was administered intravenously.
A small branch of the left pulmonary artery and one femoral artery were catheterized with polyethylene catheters for measurement of pressure. One femoral vein was also catheterized for administration of test substances. In some animals central venous pressure was measured.
Two cyclic ether endoperoxide analogues and prostaglandin F2 were provided by the Upjohn Company (Bundy, 1975 Figure 1 shows the pulmonary and systemic vascular effects of the 9a, 1 la-(epoxymethano) analogue in the left ventricular bypass preparation. Following intravenous administration, the onset of the pulmonary pressor action of both endoperoxide analogues was rapid and the duration of the pressor response was generally longer than was observed with prostaglandin F2a. The mean percentage increase in pulmonary arterial Table 1 could be achieved. The onset of elevation of pulmonary arterial pressure followed the onset of increase in systemic arterial pressure because of the delay in the drug reaching the pulmonary circulation.
Discussion
Our interest in the cardiovascular actions of the endoperoxides stems from previous studies with their fatty acid precursor arachidonic acid, which consistently produced a systemic depressor response, pulmonary vasoconstriction and a variable effect on myocardial contractile force in dogs (Rose, Johnson, Ramwell & Kot, 1974; Kot, Johnson, Ramwell & Rose, 1975; Wicks, Rose, Johnson, Ramwell & Kot, 1976) . These haemodynamic changes were completely blocked by pretreatment of the animal with aspirin or indomethacin suggesting that arachidonic acid itself is not vasoactive and that one or more compounds generated from arachidonic acid via the cyclooxygenase pathway are responsible for the observed haemodynamic changes. Our attention was directed to the endoperoxides since they are the first of the intermediate compounds formed from arachidonic acid and have been shown to be potent vasoactive compounds (Needleman, Minkes & Raz, 1976) . The naturally occurring endoperoxides, prostaglandins G2 and H2 are highly unstable compounds with a biological half-life of approximately 5 min (Hamberg et al., 1975) . They produce a 'triphasic' blood pressure response when administered intravenously in guineapigs. Initially, there was a transient fall in systemic arterial pressure, which was followed by a rise in arterial pressure of short duration and finally a prolonged depressor response. Hamberg et al. (1975) concluded that the initial decline and subsequent increase in systemic arterial pressure could be explained on the basis of pulmonary and systemic vasoconstriction respectively. The prolonged a 398 1. ALTER, P.A. KOT, P.W. RAMWELL, J.C. ROSE & M.R. SHNIDER reduction of systemic arterial pressure was attributed to prostaglandin E2, which was thought to be generated during the degradation of the endoperoxides.
In intact dogs, systemic administration of these stable endoperoxide analogues produced pulmonary and systemic pressor responses and an increase in myocardial contractile force (Rose et al., 1976) . These cardiovascular actions were not blocked by pretreatment of the animals with indomethacin. The systemic arterial pressure response to the analogues was characterized by a transient initial fall in blood pressure followed by a gradual moderate increase in pressure. However, unlike prostaglandins G2 and H2 no terminal depressor response was observed with the analogues. The pulmonary arterial vasoconstriction was intense.
Because of the complex nature of the systemic arterial pressure response, the systemic and pulmonary vascular effects of the endoperoxide analogues were studied in the dog during left ventricular bypass. The results show quite clearly that the two analogues are potent pulmonary vasoconstrictor agents, as previously demonstrated (Kadowitz, Spannhake & Hyman, 1976; Rose et al., 1976) . This pulmonary pressor response was due to a direct action of the endoperoxides on pulmonary vascular smooth muscle, with both intrapulmonary arteries and veins appearing to participate in the response (McNamara, Gruetter, Hyman & Kadowitz, 1976) . The pulmonary pressor activity of the endoperoxide analogues was greater than that of prostaglandin F2a and the order of potency was approximately 20: 1 at the doses used in these studies.
In the bypass preparation, the analogues increased systemic arterial pressure indicating an increase in systemic vascular resistance since blood flow was maintained constant. A transient initial decrease in systemic arterial pressure was not observed in the bypass animals. This finding is consistent with the interpretation that the transient early decrease in systemic arterial pressure observed in the intact circulation is the result of reduced cardiac output. This decrease in cardiac output results from intense pulmonary vasoconstriction temporarily restricting pulmonary venous return to the left side of the heart. Instead of a terminal depressor response, there was a gradual return of systemic arterial pressure to control levels. Since the analogues do not convert to prostaglandin E2, Hamberg et al. (1975) may be correct in assuming that the terminal depressor response observed with prostaglandins G2 and H2 is, indeed, due to prostaglandin E2 generation.
These studies demonstrate that the haemodynamic changes induced by the endoperoxide analogues are qualitatively different from those produced by arachidonic acid. This suggests two possibilities: (i) the endoperoxide intermediates are not the primary cause of the haemodynamic changes observed with systemic administration of arachidonic acid and (ii) the cardiovascular responses induced by arachidonic acid may represent the combined actions of several compounds generated in the biosynthetic pathway from arachidonic acid to the prostaglandins.
